HistoSonics Highlights Histotripsy Platform at Spectrum Miami Oncology Conference

HistoSonics has shared an update.

The company announced its participation in the Spectrum Miami Conference, taking place January 15–17, where multiple podium presentations will address histotripsy, including its spectrum of applications and use in pancreatic cancer, led by physicians from NYU Langone and Leeds Teaching Hospitals. HistoSonics will also host hands-on live demonstrations of its Edison Histotripsy System at booth #107/108. The company emphasized that Edison’s use outside of liver applications is currently limited to clinical investigations and that it is not sponsoring or controlling the content of the featured presentations.

For investors, this conference presence underscores growing clinical and academic interest in histotripsy as a non-invasive therapeutic modality in oncology, including potential expansion into challenging indications such as pancreatic cancer. While the update does not disclose commercial metrics, regulatory progress, or new clinical data, increased visibility among oncologists and interventional specialists could support long-term adoption of the Edison system and strengthen HistoSonics’ positioning within the interventional oncology and surgical device market. The explicit limitation to clinical investigations outside liver applications highlights that broader revenue generation will depend on future regulatory clearances and successful clinical outcomes, but sustained engagement at multidisciplinary conferences suggests momentum in clinician awareness and potential future demand.